Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 15/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.66 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.63 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1603767 | 0.86 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 | |
| SCHEMBL1604348 | 0.85 | PDPK1 (0.70) | PDPK1PIK3CAPIK3CG | |
| SCHEMBL1603418 | 0.83 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGNTRK1CCNT1 | |
| SCHEMBL1604708 | 0.82 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 | |
| SCHEMBL1456058 | 0.81 | PDPK1 (0.79) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 | |
| SCHEMBL1604923 | 0.81 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGNTRK1CCNT1 | |
| SCHEMBL1604236 | 0.80 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 | |
| SCHEMBL1603480 | 0.79 | PDPK1 (0.79) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 | |
| SCHEMBL27826957 | 0.78 | PDPK1 (0.67) | PDPK1PIK3CAPIK3CGNTRK1CCNT1 | |
| SCHEMBL1603489 | 0.78 | PDPK1 (1.00) | PDPK1PIK3CAPIK3CGCCNT1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | claimed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | claimed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | claimed |
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2155745-B1 | 6-(pyrrolopyridinyl)-pyrimidine-2-yl-amine derivatives and their use for the treatment of cancers and aids | MERCK PATENT GMBH (DE) | 2015-01-28 | — | — | EP | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546390-B2 | 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and AIDS | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MERCK PATENT GMBH (DE) | 2011-04-07 | — | — | US | disclosed |
| WO-2008155000-A1 | 6-(PYRROLOPYRIDINYL)-PYRIMIDINE-2-YL-AMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082140-A1 | 6-(PYRROLOPYRIDINYL) PYRIMIDIN-2-YLAMINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF CANCER AND AIDS. | MKI67, TYMP, TK2 | PDPK1 386/4885PIK3CA 812/4885PIK3CG 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.